Spanish Biotech CONNECTA Therapeutics Secures €3.1 Million to Advance Fragile X Syndrome Treatment
Spanish biotech CONNECTA Therapeutics raised €3.1 million, led by Clave Capital, to fund the next phase of clinical trials for a novel treatment targeting Fragile X syndrome, a neurodevelopmental disorder with no approved therapies.
